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Summary A specific two-site ELISA for human epidermal growth factor (hEGF) has been used to measure
urinary hEGF/creatinine ratios in 30 normal subjects, 30 hospital in-patients with breast cancer and 30
hospital in-patients with colonic or rectal cancer. There was no significant difference between patients with
breast cancer and controls. Although a statistically significant difference between patients with colorectal
cancer and controls was observed, the biological significance of this observation is doubtful. No clear effect of
the presence of breast or colorectal carcinoma on the urinary excretion of hEGF has been observed.
Human epidermal growth factor (hEGF, urogastrone) is a
heat- and acid-stable polypeptide of molecular weight 6000,
originally isolated from human urine and found to be iden-
tical to the gastric anti-secretory hormone, B urogastrone
(Gregory et al., 1977). It is involved in the regulation of
proliferation of numerous cell types. Its receptor is the pro-
duct of the C-erb-B proto-oncogene, suggesting a possible
role for hEGF in malignant transformation (Downward et
al., 1984). Three previous studies have demonstrated elevated
levels of urinary hEGF in patients with malignant disease,
suggesting that it may have a clinical application as a tumour
marker (Uchihashi et al., 1983; Kurobe et al., 1985; Strom-
'berg et at., 1989). In contrast, Matilla et al. (1988) have only
been able to demonstrate elevated levels in one group of
patients with cancer, and they suggest a hormonal mechan-
ism for this.
We have measured immunoreactive urinary hEGF using a
2-site ELISA in a group of 30 patients with carcinoma of the
breast, 30 with carcinoma of the colon or rectum, and com-
pared these with 30 normal subjects.
Materials and methods
Subjects and samples
Spot urine samples were used in this study, and urinary
hEGF expressed as hEGF/creatinine ratios. Dailey et al.
(1978) have demonstrated the linear relationship between
urinary hEGF and urinary creatinine, and the use of this
ratio eliminates the requirement for 24 h urine collections to
assess hEGF excretions. Ten to 20 ml samples were collected
from 60 patients and 30 normal subjects. When immediate
analysis was not possible, specimens were frozen and stored
at -70'C. Immediately before assay, samples were thawed
and centrifuged to remove precipitated material. For patients
with carcinomas, samples were collected on admission to
hospital, before surgery. They were analysed only if the
diagnosis of breast, or colorectal, carcinoma was confinned
histologically. Normal subjects comprised laboratory person-
nel and ward staff. The control subjects in this study were
not matched for sex or age since, in our initial studies, no
obvious trend was seen for differences in urinary hEGF with
sex or with increasing age. Although marked age differences
in urinary hEGF are reported, these are most distinct up to
puberty, and the differences thereafter are much smaller
(Matilla et al., 1985). The characteristics of the three groups
are shown in Table I.
Assayprocedures
Urinary hEGF was measured by a specific 2-site ELISA
using a mouse monoclonal anti-hEGF, 3D3 (hybridoma
generously donated by Dr K. Nishikawa, Uchinda, Japan)
(Yoshitake & Nishikawa, 1985), as the capturing antibody,
and a sheep polyclonal anti-hEGF as the secondary anti-
body. A recombinant hEGF (Searle Research and Develop-
ment, UK) was employed as the standard. All samples were
assayed in duplicate and at several dilutions. The assay
system is highly specific for hEGF. Mouse salivary gland
EGF and human TGF, when tested up to a concentration of
12 mg ml-' failed to be detected in the ELISA. The assay
detects hEGF in the urine to a level of 50 pg ml-'. Figure 1
-demonstrates typical results with recombinant and native
urinary hEGF, demonstrating parallel dilution curves for
both.
Table I Patient characteristics
Median age
Patient group No. Male:female (range)
Normal subjects 30 18:12 32 (23-66)
Colorectal carcinoma 30 13:17 61 (47-72)
Breast carcinoma 30 0:30 59 (36-68)
1.2
1.0
0
1.2 0.12
Concentration ng ml-'
0.01
Figure I Dilution curves for recombination hEGF and human
urine assayed by 2-site ELISA for hEGF. 0 0 Recombinant
hEGF; A--A Urine.
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Urinary creatinine levels were measured in the Department
of Chemical Pathology, Southampton General Hospital, on a
Beckmann-Astra auto analyser using the kinetic method of
Jaffe (Lustgarten & Wenk, 1972). Statistical analysis was
performed using the Students t-test.
Results
The results for hEGF/creatinine are shown in Table II and
Figure 2. No sex difference in hEGF/creatinine was apparent
and no clear relationship with age was found. The difference
in hEGF/creatinine between normal subjects and patients
with colorectal carcinoma achieves statistical significance
at the 95% level. No significant difference was observed
between normal subjects and patients with breast carcinomas.
Despite the statistically significant difference, Figure 2 illus-
trates a wide variability within each group, and considerable
overlap.
Discussion
In this study, a statistically significant difference was observ-
ed between urinary hEGF levels of patients with colorectal
carcinomas, compared with normal subjects. The biological
significance of this observation is, however, doubtful, in view
of the large overlap demonstrated in Figure 2. It appears to
have no clinical application as a marker of colorectal or
breast carcinoma in this study. Although the control group
in this study was not age and sex matched, no obvious
differences in urinary hEGF between sexes, or at different
ages, were observed. Sex and age related differences in
urinary hEGF have been reported (Matilla, 1986), but their
magnitude in the 20-60 year age group is small and there-
fore, the lack of matched controls is unlikely to have affected
these results significantly.
In contrast to the findings in this study, Uchihashi et al.
(1983) measured urinary immunoreactive hEGF/creatinine
levels in a series of patients with various malignancies. They
demonstrated supranormal levels in patients with carcinomas
of the lung, maxilla, oesophagus, stomach, thyroid, breast
and cervix, and in lymphoma, leukaemia and myeloma.
Kurobe et al. (1985) demonstrated elevated levels of urinary
hEGF/creatinine in patients with gastric pathology. Con-
versely, Cartlidge & Elder (1988) demonstrated reduced
urinary hEGF/creatinine levels in patients with gastric car-
cinomas, compared with age and sex matched controls.
A report of a single patient with an astrocytoma describes
a high molecular weight form of hEGF in the urine, present
at high level, which could not be detected following complete
surgical excision of the tumour (Stromberg et al., 1987). In a
more recent study, Matilla et al. (1988) studied 97 adults with
carcinomas of the bladder, kidney, stomach, colon, rectum,
breast, cervix and endometrium. Significantly elevated
urinary hEGF was found only in females with endometrial
carcinoma, and the levels did not return to normal after
surgery. The authors suggested that this elevation may be
mediated by high oestrogen levels.
In the light of current knowledge, the lack of correlation
Table II Urinary hEGF/creatinine levels
Mean hEGFI Standard P (Student's
Patient group creatinine deviation t test)
Normal subject 5.6 2.4 )004
Colorectal carcinoma 9.4 9.4 l 1 024
Breast carcinoma 6.6 3.5 0
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Figure 2 Distribution of hEGF/creatinine ratios amongst study
group.
between urinary hEGF and malignant disease is not surpris-
ing. Evidence for the excessive production of hEGF by
tumours is poor, and although immunoreactive hEGF can be
found in tumours on histological staining, it has only rarely
been found in tumour extracts (Mori et al., 1987). Further-
more, most urinary hEGF is derived from the kidneys (Rall
et al., 1985; Gubits et al., 1986) and, even if tumour-derived
hEGF were excreted into the urine, the amounts would be
unlikely to produce a significant increase. Where elevated
levels of hEGF have been found, this may represent an
indirect effect of a tumour product on renal hEGF produc-
tion. It has been shown that athymic rats bearing a human
tumour xenograft, A673, have increased urinary levels of rat
EGF, with no human equivalent present (Hudgins et al.,
1988).
This study, therefore, has failed to demonstrate any effect
of breast or colon carcinomas on the urinary excretion of
hEGF compared with normal subjects.
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